TMCnet News
Expression Analysis Announces 2014 Grant WinnersExpression Analysis (EA), a Quintiles company, today announced the winners of a grant program that provides scientists with leading-edge products and services to advance genomics research. In this sixth year of the program, EA and co-sponsor, Illumina, awarded two fully funded research grants to investigate genomic data locked within Formalin-Fixed, Paraffin Embedded (FFPE) tumor samples - a largely untapped data pool that can help enhance researchers' understanding of cancer biology. Anne Bowcock, recipient of an EA grant (Photo: Business Wire) After a rigorous review of nearly 700 submissions by a distinguished panel of judges, two researchers were selected to receive grants. The recipients include:
"We are honored to support the efforts of Dr. Bowcock and Dr. Huang in their quests to better understand the underlying science of colon and ovarian cancers. We hope that their research yields insights which will one day improve outcomes for individuals with these devastating diseases," said Tina Nova, senior vice president and general manager, oncology for Illumina. About EA EA, a Quintiles company, provides cutting-edge genomic sequencing, gene expression, genotyping, and bioinformatics services to the world's largest pharmaceutical companies, diagnostic test developers, government agencies, and academic labs. Projects are conducted under clinical-grade quality control, ensured through CLIA certification, GCP compliance, and adherence to CLSI guidelines as applicable to the testing performed. EA's bioinformatics staff are key contributors to the Food and Drug Administration's MicroArray Quality Control (MAQC) and Sequencing Quality Control (SEQC) studies, which aim to improve standards and quality measures for reliable use of next-generation sequencing and gene expression technologies in clinical practice and regulatory decision-making. As part of its mission to improve human health, EA has donated more than $2.8 million towards academic genomic research grants and its "Leave Your Fingerprint on the Cure" Program for pediatric cancer hosted at the American Society for Human Genetics annual meeting. About Quintiles Quintiles (NYSE: Q), a Fortune 500 company, is the world's largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013's top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com. Click here to subscribe to Mobile Alerts for Quintiles. Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150115005099/en/ |